ANTLER trial shows positive initial data for CB-010 anti-CD19 allogeneic CAR T-cell therapy

FDA and EC approve Opdivo IO combinations in classical Hodgkin Lymphoma

FDA granted approval of Opdivo (nivolumab) in combination with doxorubicin, vinblastine, and dacarbazine for the treatment of adult and pediatric patients 12 years and older with previously untreated Stage 3 or 4 classical Hodgkin Lymphoma.

March 27, 2026

Vol.52 No.12

In Brief

Kathleen N. Moore appointed deputy director and director of Phase I Oncology Trials Program at Fred & Pamela Buffett Cancer Center

The Fred & Pamela Buffett Cancer Center has named Kathleen N. Moore as deputy director and director of Phase I Oncology Trials.

March 20, 2026

Vol.52 No.11

Clinical Roundup

Atirmociclib combination produces positive topline results in phase II trial in second-line MBC indication

Positive topline results have come out of the randomized phase II FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or everolimus plus exemestane, in people with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer who had received prior cyclin-dependent kinase 4/6 inhibitor-based treatment.

March 20, 2026

Vol.52 No.11

Drugs & Targets

Sartorius launches platform to boost efficiency in cell therapy production

Sartorius is launching an integrated system for the production and quality control of autologous cell therapies. The modular Eveo Cell Therapy Platform is designed to address structural manufacturing bottlenecks that limit scalability and patient access to transformative treatments such as CAR T therapies.

March 20, 2026

Vol.52 No.11

Drugs & Targets

START, Trialing collaborate to expand access to oncology clinical trials across Europe

The START Center for Cancer Research, a community-based network of clinical trial sites specializing in early-phase oncology trials, announced a strategic partnership with Trialing, a platform dedicated to connecting physicians and patients to clinical trials, helping physicians rapidly identify, evaluate, and refer patients to appropriate studies.

March 20, 2026

Vol.52 No.11

Cancer History Project

The murder of Alexei Navalny is part of Russia’s macabre fascination with poisons
A gallop through history of poisonings—from hemlock, to mustard gas, to Polonium-210, to dart frog poison

Poisoning one’s political rivals has a long history. In 399 B.C., an Athenian court found Socrates guilty of “impiety and the corruption of youth” and ordered him to drink a fatal dose of hemlock.

March 13, 2026

Vol.52 No.10

By Robert Peter Gale

ANTLER trial shows positive initial data for CB-010 anti-CD19 allogeneic CAR T-cell therapy

YOU MAY BE INTERESTED IN

FDA and EC approve Opdivo IO combinations in classical Hodgkin Lymphoma

Kathleen N. Moore appointed deputy director and director of Phase I Oncology Trials Program at Fred & Pamela Buffett Cancer Center

Atirmociclib combination produces positive topline results in phase II trial in second-line MBC indication

Sartorius launches platform to boost efficiency in cell therapy production

START, Trialing collaborate to expand access to oncology clinical trials across Europe

The murder of Alexei Navalny is part of Russia’s macabre fascination with poisons
A gallop through history of poisonings—from hemlock, to mustard gas, to Polonium-210, to dart frog poison

Renew today!

Subscriber content

Never miss an issue!

Login

ANTLER trial shows positive initial data for CB-010 anti-CD19 allogeneic CAR T-cell therapy

YOU MAY BE INTERESTED IN

FDA and EC approve Opdivo IO combinations in classical Hodgkin Lymphoma

Kathleen N. Moore appointed deputy director and director of Phase I Oncology Trials Program at Fred & Pamela Buffett Cancer Center

Atirmociclib combination produces positive topline results in phase II trial in second-line MBC indication

Sartorius launches platform to boost efficiency in cell therapy production

START, Trialing collaborate to expand access to oncology clinical trials across Europe

The murder of Alexei Navalny is part of Russia’s macabre fascination with poisonsA gallop through history of poisonings—from hemlock, to mustard gas, to Polonium-210, to dart frog poison

Never miss an issue!

Login

The murder of Alexei Navalny is part of Russia’s macabre fascination with poisons
A gallop through history of poisonings—from hemlock, to mustard gas, to Polonium-210, to dart frog poison